Avalo Therapeutics is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. The company’s lead asset, abdakibart, is currently advancing through a Phase 2 clinical trial for hidradenitis suppurativa.
For the year ended December 31, 2025, Avalo reported total net revenues of $59 (in thousands). Additionally, the company recorded a basic and diluted net loss per share of $5.84.
Avalo reported a total net loss of $78.3 million for the 2025 fiscal year. This was heavily driven by $50.1 million in research and development expenses to support their clinical trials. Moving forward, the company holds $98.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025, which is expected to successfully fund operations into 2028.